Development of anti-Epstein-Barr virus (EBV) inhibitors and imaging agents for nasopharyngeal carcinoma (NPC); Cancer immunology, cancer cachexia and metabolism, and tumor metastasis of NPC; Identification of therapeutic targets and potential drugs for NPC and esophageal squamous cell carcinoma using normal and cancer organoid models.

Dr. Lung has more than 20 years research experience on translational cancer biology and genomics of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. He has published more than 50 scientific articles and received > 15M research and related grants. As the first and/or corresponding author, he has published 25 scientific articles (which include 21 research papers, 2 review articles, and 2 book chapters) in high impact international journals including Advanced Science (Impact Factor, IF = 15.8, 1 article), Cancer Research (IF = 12.7, 2 articles), JACS Au (IF = 12.35, 1 article), Proc Natl Acad Sci U S A. (IF = 11.2, 1 article), Journal of Experimental & Clinical Cancer Research (IF = 11.16, 1 article), Seminars in Cancer Biology (IF = 9.955, 1 article), Oncogene (IF = 9.867, 3 articles), Nanoscale (IF = 7.79, 1 article), International Journal of Cancer (IF = 7.396, 4 articles), Cancers (IF = 6.639, 1 article), Frontiers in Oncology (IF = 5.66, 1 article), etc.